Show simple item record

dc.contributor.authorRuiz, Susana
dc.contributor.authorDomenech, Mirian
dc.contributor.authorAntequera, María Luisa
dc.contributor.authorGarcía, Pedro
dc.contributor.authorGarcía, Ernesto
dc.contributor.authorCorsini, Bruno 
dc.contributor.authorAguinagalde, Leire 
dc.contributor.authorFenoll, Asuncion 
dc.contributor.authorYuste, Jose Enrique 
dc.date.accessioned2020-06-11T09:21:39Z
dc.date.available2020-06-11T09:21:39Z
dc.date.issued2016
dc.identifier.citationVaccine . 2016 Dec 7;34(50):6148-6157.es_ES
dc.identifier.urihttp://hdl.handle.net/20.500.12105/10341
dc.description.abstractThe cell wall glucosaminidase LytB of Streptococcus pneumoniae is a surface exposed protein involved in daughter cell separation, biofilm formation and contributes to different aspects of the pathogenesis process. In this study we have characterized the antibody responses after immunization of mice with LytB in the presence of alhydrogel as an adjuvant. Enzyme-linked immunosorbent assays measuring different subclasses of immunoglobulin G, demonstrated that the antibody responses to LytB were predominantly IgG1 and IgG2b, followed by IgG3 and IgG2a subclasses. Complement-mediated immunity against two different pneumococcal serotypes was investigated using sera from immunized mice. Immunization with LytB increased the recognition of S. pneumoniae by complement components C1q and C3b demonstrating that anti-LytB antibodies trigger activation of the classical pathway. Phagocytosis assays showed that serum containing antibodies to LytB stimulates neutrophil-mediated phagocytosis against S. pneumoniae. Animal models of infection including invasive pneumonia and sepsis were performed with two different clinical isolates. Vaccination with LytB increased bacterial clearance and induced protection demonstrating that LytB might be a good candidate to be considered in a future protein-based vaccine against S. pneumoniae.es_ES
dc.description.sponsorshipThis work was supported by grants SAF2012-39444-C01/02 from Ministerio de Economía y Competitividad (MINECO). Centro de Investigación Biomédica en Red de Enfermedades Respiratorias (CIBERES) is an initiative of ISCIII. BC and LA were supported, respectively, by a fellowship from the Brazilian Program Ciencia Sem Fronteiras (CsF) from Conselho Nacional de Desenvolvimento Científico e Tecnológico (CNPq) and by an FPI fellowship from MINECO. The authors wish to thank Sandra Martín for technical assistancees_ES
dc.language.isoenges_ES
dc.publisherElsevieres_ES
dc.relation.isversionofPostprintes_ES
dc.rights.urihttp://creativecommons.org/licenses/by-nc-nd/4.0/*
dc.subject.meshPhagocytosis es_ES
dc.subject.meshAdjuvants, Immunologices_ES
dc.subject.meshAluminum Hydroxide es_ES
dc.subject.meshAnimals es_ES
dc.subject.meshAntibodies, Bacterial es_ES
dc.subject.meshComplement System Proteins es_ES
dc.subject.meshDisease Models, Animales_ES
dc.subject.meshEnzyme-Linked Immunosorbent Assay es_ES
dc.subject.meshFemale es_ES
dc.subject.meshImmunoglobulin G es_ES
dc.subject.meshImmunologic Factors es_ES
dc.subject.meshMale es_ES
dc.subject.meshMice, Inbred BALB C es_ES
dc.subject.meshN-Acetylmuramoyl-L-alanine Amidase es_ES
dc.subject.meshNeutrophils es_ES
dc.subject.meshPneumococcal Infections es_ES
dc.subject.meshPneumococcal Vaccines es_ES
dc.subject.meshPneumonia, Bacterial es_ES
dc.subject.meshSepsis es_ES
dc.subject.meshStreptococcus pneumoniae es_ES
dc.subject.meshTreatment Outcome es_ES
dc.titleImmunization with LytB protein of Streptococcus pneumoniae activates complement-mediated phagocytosis and induces protection against pneumonia and sepsis.es_ES
dc.typeArtículoes_ES
dc.rights.licenseAttribution-NonCommercial-NoDerivatives 4.0 Internacional*
dc.identifier.pubmedID27840016es_ES
dc.format.volume34es_ES
dc.format.number50es_ES
dc.format.page6148-6157es_ES
dc.identifier.doi10.1016/j.vaccine.2016.11.001es_ES
dc.contributor.funderMinisterio de Economía y Competitividad (España)es_ES
dc.contributor.funderCentro de Investigación Biomedica en Red - CIBERes_ES
dc.contributor.funderConselho Nacional de Desenvolvimento Científico e Tecnológico (Brasil)es_ES
dc.description.peerreviewedes_ES
dc.identifier.e-issn1873-2518es_ES
dc.relation.publisherversionhttps://doi.org/10.1016/j.vaccine.2016.11.001es_ES
dc.identifier.journalVaccinees_ES
dc.repisalud.centroISCIII::Centro Nacional de Microbiologíaes_ES
dc.repisalud.institucionISCIIIes_ES
dc.relation.projectIDinfo:eu_repo/grantAgreement/ES/SAF2012-39444-C01/02es_ES
dc.rights.accessRightsinfo:eu-repo/semantics/openAccesses_ES


Files in this item

Acceso Abierto
Thumbnail

This item appears in the following Collection(s)

Show simple item record

Attribution-NonCommercial-NoDerivatives 4.0 Internacional
This item is licensed under a: Attribution-NonCommercial-NoDerivatives 4.0 Internacional